Jennerex Appoints Samantha Miller as Vice President of Corporate Development



    SAN FRANCISCO, Jan. 13 /CNW/ -- Jennerex, Inc. (San Francisco, CA and
Ottawa, Canada) a clinical-stage biotherapeutics company, is pleased to
announce that Samantha Miller has been appointed to the position of Vice
President of Corporate Development.
    Ms. Miller has over 15 years of biotechnology and pharmaceutical business
development experience, and has negotiated, executed and managed numerous
global partnerships, as well as regional partnerships in the United States,
Europe, Japan and elsewhere. She has been involved in executing over 30
partnerships and licenses, with companies such as GlaxoSmithKline, Eli Lilly,
Johnson & Johnson, AstraZeneca, Astellas and others.
    Ms. Miller has held senior positions in business development, including
the title of Vice President, in various companies including Anesiva,
Theravance, Scios Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble
Pharmaceuticals.
    "Samantha is an outstanding addition to our executive management team. As
Jennerex continues to report compelling Phase 1 and 2 clinical data from its
oncology programs, Samantha joins us at an opportune time for the development
of additional strategic partnerships," said David H. Kirn, M.D., President and
Chief Executive Officer. "We have clear regulatory pathways to large global
cancer markets with multiple products, and Samantha's addition to the Jennerex
team further endorses the potential of the Company's product platform," added
Dr. Kirn.
    Ms. Miller holds a BS in Biochemistry/ Cell Biology from UCSD, and she
holds Masters degrees in both Immunology and in Business Administration (MBA)
from the University of Rochester.
    
    About Jennerex
    
    Jennerex is a clinical-stage biotherapeutics company focused on the
development and commercialization of first-in-class, breakthrough targeted
oncolytic products for cancer. The company's lead product JX-594, currently in
an international Phase 2 trial for primary liver cancer, demonstrated
promising Phase 1 efficacy and safety results in patients with a diverse array
of common large market cancers. Jennerex's products target, attack and
eradicate cancers through a novel and potent oncolytic mechanism that is
dependent on highly-specific replication of the company's poxviruses in cancer
cells. These products simultaneously stimulate the body's immune response to
the cancer. Of note, this mechanism of action and the results in patients to
date put the company's product class in a leadership position. Jennerex's
position is in marked contrast to gene therapy and standard cancer vaccine
approaches. For more information about Jennerex and the company's robust
pipeline and three clinical-stage products, please visit
http://www.jennerex.com.




For further information:

For further information: Samantha Miller, MSc. MBA, VP Corporate
Development of Jennerex, Inc., +1-415-281-8886, smiller@jennerex.com Web Site:
http://www.jennerex.com

Organization Profile

JENNEREX, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890